LXRX (STOCKS)
Lexicon Pharmaceuticals, Inc.
$1.309900
-0.060100 (-4.39%)
Prev close: $1.370000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Michael Exton
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $520.04M
- Employees
- 103
- P/E (TTM)
- -6.91
- P/B (TTM)
- 4.14
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
5
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.04 | $-0.07 | +0.0273 | +40.56% |
|
Jun 2025 (Q2)
|
$0.01 | $-0.08 | +0.0891 | +112.64% |
|
Mar 2025 (Q1)
|
$-0.07 | $-0.10 | +0.0295 | +29.65% |
|
Dec 2024 (Q4)
|
$-0.09 | $-0.13 | +0.0399 | +30.72% |
Financial Statements
| Revenues | $70.86M |
| Benefits Costs and Expenses | $137.73M |
| Cost Of Revenue | $421.00K |
| Costs And Expenses | $137.73M |
| Gross Profit | $70.44M |
| Operating Expenses | $137.31M |
| Selling, General, and Administrative Expenses | $60.82M |
| Research and Development | $76.49M |
| Operating Income/Loss | -$66.87M |
| Income/Loss From Continuing Operations After Tax | -$68.58M |
| Income/Loss From Continuing Operations Before Tax | -$66.97M |
| Net Income/Loss | -$68.58M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$68.58M |
| Net Income/Loss Available To Common Stockholders, Basic | -$68.58M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.19 |
| Diluted Earnings Per Share | -$0.19 |
| Basic Average Shares | 740,008,000 |
| Diluted Average Shares | 740,008,000 |
| Assets | $205.93M |
| Current Assets | $122.53M |
| Inventory | $158.00K |
| Other Current Assets | $122.37M |
| Noncurrent Assets | $83.40M |
| Fixed Assets | $1.98M |
| Other Non-current Assets | $81.42M |
| Liabilities | $85.77M |
| Current Liabilities | $21.72M |
| Accounts Payable | $3.80M |
| Wages | $4.79M |
| Other Current Liabilities | $13.14M |
| Noncurrent Liabilities | $64.05M |
| Equity | $120.16M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $120.16M |
| Liabilities And Equity | $205.93M |
| Net Cash Flow From Operating Activities | -$72.11M |
| Net Cash Flow From Operating Activities, Continuing | -$72.11M |
| Net Cash Flow From Investing Activities | $161.89M |
| Net Cash Flow From Investing Activities, Continuing | $161.89M |
| Net Cash Flow From Financing Activities | -$45.68M |
| Net Cash Flow From Financing Activities, Continuing | -$45.68M |
| Net Cash Flow | $44.11M |
| Net Cash Flow, Continuing | $44.11M |
| Comprehensive Income/Loss | -$68.77M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$68.90M |
| Other Comprehensive Income/Loss | -$46.72M |